CTIS2024-512472-35-00
Recruiting
Phase 1
Evaluation of safety and pharmacokinetic parameters of the PTI5803 product
Panntherapi0 sites8 target enrollmentMarch 29, 2024
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Epilepsy
- Sponsor
- Panntherapi
- Enrollment
- 8
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 1
Phase 1 study of 211At-MABG in patients with pheochromocytoma/pargangliomaPheochromocytoma, paragangliomaD010673, D010235JPRN-jRCT2021220012Shiga Tohru18
Not yet recruiting
Phase 1
Safety and pharmacokinetics of CIGB-552Solid tumorsRPCEC00000196Center for Genetic Engineering and Biotechnology (CIGB)
Active, not recruiting
Phase 1
Evaluation of the Pharmacokinetics, Safety, Tolerability and Efficacy of Entecavir (ETV)in Pediatric Subjects with Chronic Hepatitis B Virus (HBV) Infection who are HBeAg-Positive. Revised Protocol 02, incorporating Protocol Amendment 01 (v1.0, date 18-Apr-2008), and Protocol Amendment 04 (v1.0, date 05-Dec-2008).Chronic Hepatitis B Virus (HBV) InfectionMedDRA version: 8.1Level: LLTClassification code 10019743Term: Hepatitis B virus (HBV)EUCTR2005-005816-26-BEBristol-Myers Squibb International Corporation64
Active, not recruiting
Phase 1
A study of Entecavir in Pediatric Patients with Chronic Hepatitis B Virus (HBV) InfectioChronic Hepatitis B Virus (HBV) InfectionMedDRA version: 16.1 Level: LLT Classification code 10019743 Term: Hepatitis B virus (HBV) System Organ Class: 100000004848Therapeutic area: Diseases [C] - Virus Diseases [C02]EUCTR2005-005816-26-GBBristol-Myers Squibb International Corporation64
Active, not recruiting
Not Applicable
A study of Entecavir in Pediatric Patients with Chronic Hepatitis B Virus (HBV) InfectioEUCTR2005-005816-26-Outside-EU/EEABristol-Myers Squibb International Corporation64